|
|
|
|
|||||
|
|
|
GSK plc (NYSE:GSK) is included among the 12 Best European Dividend Stocks to Buy Now.
On October 31, JPMorgan lowered its price target on GSK plc (NYSE:GSK) to 1,440 GBp from 1,550 GBp while maintaining an Underweight rating on the stock, according to a report by The Fly.
GSK plc (NYSE:GSK) shares have risen nearly 40% since the start of 2025, driven by strong third-quarter results and an improved 2025 outlook. The company reported sales of £8.5 billion, up about 7% year-on-year, with the Specialty Medicines division performing particularly well, growing 16% to £3.4 billion.
Oncology sales were a major highlight, increasing almost 39%, reflecting the strength of GSK plc (NYSE:GSK)’s new drug portfolio following the divestment of its pharmaceutical arm. The company’s performance has also been supported by positive clinical updates, especially for its respiratory biologics and RSV vaccine.
GSK plc (NYSE:GSK) is a British multinational pharmaceutical company engaged in the research, development, and manufacture of specialty medicines, vaccines, and general medicines.
While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Best 52-Week Low Dividend Stocks to Invest In and 15 Stocks with Highest Dividend to Invest In
Disclosure: None.
| Nov-19 | |
| Nov-18 | |
| Nov-17 | |
| Nov-14 | |
| Nov-14 | |
| Nov-13 | |
| Nov-11 | |
| Nov-06 | |
| Nov-06 | |
| Nov-06 | |
| Nov-05 | |
| Nov-05 | |
| Nov-05 | |
| Nov-04 | |
| Nov-04 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite